CFD 属于复杂的高风险金融工具,其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作,以及是否能够接受高额亏损的风险。

交易 ARCA Biopharma - ABIO CFD

-
0%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 -
多头隔夜费

Long position overnight fee


Margin. Your investment $1,000.00
隔夜费用 -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

前往平台
-0.025457%
空头隔夜费

Short position overnight fee


Margin. Your investment $1,000.00
隔夜费用 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

前往平台
0.003235%
隔夜费时间 21:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

关键数据
前收盘价* N/A
开仓* N/A
1 年变化* N/A
日范围* N/A
52 周范围 1.85-2.70
平均交易量(10 天) 33.81K
平均交易量(3 个月) 538.64K
市值 30.41M
市盈率 -100.00K
流通股 14.41M
收入 N/A
EPS -0.56
股息(收益率 %) N/A
贝塔 1.36
下一个财报发布日期 Jul 31, 2023

所有数据都是由Refinitiv提供的, 除了标有星号的数据, 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平仓 Change Change (%) 開倉 High Low

ARCA Biopharma Events

时间(协调世界时) (UTC) 国家/地区 事件
Monday, July 31, 2023

时间(协调世界时) (UTC)

10:59

国家/地区

US

事件

Q2 2023 ARCA Biopharma Inc Earnings Release
Q2 2023 ARCA Biopharma Inc Earnings Release

Forecast

-

Previous

-
Thursday, October 26, 2023

时间(协调世界时) (UTC)

10:59

国家/地区

US

事件

Q3 2023 ARCA Biopharma Inc Earnings Release
Q3 2023 ARCA Biopharma Inc Earnings Release

Forecast

-

Previous

-
查看所有活動
  • 年度
  • 每季度
2022 2021 2020 2019 2018
总收入 0 0 0 0 0
总营业费用 10.596 19.335 9.766 5.814 8.118
销售/一般/行政费用,总计 5.847 5.503 4.774 3.981 3.879
研究与开发 4.749 13.832 4.992 1.833 4.239
营业收入 -10.596 -19.335 -9.766 -5.814 -8.118
利息收入(费用),非经营净值 0.675 0.013 0.019 0.165 0.154
税前净收入 -9.926 -19.322 -9.747 -5.649 -7.964
税后净收入 -9.926 -19.322 -9.738 -5.482 -7.933
未计算非常项目前的净收益 -9.926 -19.322 -9.738 -5.482 -7.933
净收入 -9.926 -19.322 -9.738 -5.482 -7.933
普通股股东可获收益 (不含非经常性项目) -9.926 -19.322 -9.738 -5.482 -7.933
普通股股东可获收益 (含非經常性項目) -9.926 -19.322 -9.738 -5.482 -7.933
摊薄净收入 -9.926 -19.322 -9.738 -5.482 -7.933
摊薄后加权平均股 14.4101 13.9039 4.71024 1.32123 0.76939
扣除特别项目的每股摊薄盈利 -0.68882 -1.38968 -2.06741 -4.14915 -10.3107
每股正常摊薄盈利 -0.68882 -1.38968 -2.06741 -4.14915 -10.3107
其他,净值 -0.005
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
总收入 0 0 0 0 0
总营业费用 1.796 1.548 2.552 3.219 3.277
销售/一般/行政费用,总计 1.406 1.487 1.528 1.734 1.098
研究与开发 0.39 0.061 1.024 1.485 2.179
营业收入 -1.796 -1.548 -2.552 -3.219 -3.277
利息收入(费用),非经营净值 0.45 0.374 0.222 0.072 0.007
税前净收入 -1.346 -1.174 -2.333 -3.147 -3.272
税后净收入 -1.346 -1.174 -2.333 -3.147 -3.272
未计算非常项目前的净收益 -1.346 -1.174 -2.333 -3.147 -3.272
净收入 -1.346 -1.174 -2.333 -3.147 -3.272
普通股股东可获收益 (不含非经常性项目) -1.346 -1.174 -2.333 -3.147 -3.272
普通股股东可获收益 (含非經常性項目) -1.346 -1.174 -2.333 -3.147 -3.272
摊薄净收入 -1.346 -1.174 -2.333 -3.147 -3.272
摊薄后加权平均股 14.4101 14.4101 14.4101 14.4101 14.4101
扣除特别项目的每股摊薄盈利 -0.09341 -0.08147 -0.1619 -0.21839 -0.22706
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.09341 -0.08147 -0.1619 -0.21839 -0.22706
其他,净值 0 0 -0.003 0 -0.002
  • 年度
  • 每季度
2022 2021 2020 2019 2018
流动资产总额 42.699 54.421 49.968 8.48 6.777
现金和短期投资 42.445 53.359 49.071 8.363 6.608
现金等价物 42.445 53.359 49.071 8.363 6.608
短期投资 0
Other Current Assets, Total 0.254 1.062 0.897 0.117 0.169
Total Assets 43.085 54.924 50.429 8.536 6.825
Property/Plant/Equipment, Total - Net 0.368 0.485 0.449 0.032 0.024
Property/Plant/Equipment, Total - Gross 0.572 0.68 0.699 0.399 0.398
Accumulated Depreciation, Total -0.204 -0.195 -0.25 -0.367 -0.374
Long Term Investments
Other Long Term Assets, Total 0.018 0.018 0.012 0.024 0.024
Total Current Liabilities 1.132 3.498 3.499 0.926 0.793
Accounts Payable 0.334 1.117 1.773 0.418 0.23
Accrued Expenses 0.798 2.381 1.726 0.508 0.563
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 1.412 3.881 3.908 0.926 0.793
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.28 0.383 0.409 0
Total Equity 41.673 51.043 46.521 7.61 6.032
Common Stock 0.014 0.014 0.01 0.002 0.014
Additional Paid-In Capital 225.061 224.505 200.665 152.024 144.952
Retained Earnings (Accumulated Deficit) -183.402 -173.476 -154.154 -144.416 -138.934
Other Equity, Total
Total Liabilities & Shareholders’ Equity 43.085 54.924 50.429 8.536 6.825
Total Common Shares Outstanding 14.4101 14.4101 9.54815 1.59407 0.77356
Preferred Stock - Non Redeemable, Net 0 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
流动资产总额 41.702 42.699 44.55 47.655 50.539
现金和短期投资 40.85 42.445 43.939 46.437 49.059
现金等价物 40.85 42.445 43.939 46.437 49.059
Other Current Assets, Total 0.852 0.254 0.611 1.218 1.48
Total Assets 42.059 43.085 44.965 48.101 51.014
Property/Plant/Equipment, Total - Net 0.339 0.368 0.397 0.428 0.457
Property/Plant/Equipment, Total - Gross 0.547 0.572 0.598 0.632 0.655
Accumulated Depreciation, Total -0.208 -0.204 -0.201 -0.204 -0.198
Other Long Term Assets, Total 0.018 0.018 0.018 0.018 0.018
Total Current Liabilities 1.266 1.132 1.937 2.809 2.719
Accounts Payable 0.366 0.334 0.593 1.11 1.014
Accrued Expenses 0.9 0.798 1.344 1.699 1.705
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 1.528 1.412 2.238 3.138 3.076
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.262 0.28 0.301 0.329 0.357
Total Equity 40.531 41.673 42.727 44.963 47.938
Common Stock 0.014 0.014 0.014 0.014 0.014
Additional Paid-In Capital 225.265 225.061 224.941 224.844 224.672
Retained Earnings (Accumulated Deficit) -184.748 -183.402 -182.228 -179.895 -176.748
Total Liabilities & Shareholders’ Equity 42.059 43.085 44.965 48.101 51.014
Total Common Shares Outstanding 14.4101 14.4101 14.4101 14.4101 14.4101
Preferred Stock - Non Redeemable, Net 0
  • 年度
  • 每季度
2022 2021 2020 2019 2018
净收入/起跑线 -9.926 -19.322 -9.738 -5.482 -7.933
经营活动产生的现金 -10.912 -18.762 -7.725 -4.801 -8.244
经营活动产生的现金 0.02 0.016 0.008 0.018 0.022
非现金物品 0.655 0.572 0.128 0.222 0.275
已付现金利息 0 0 0.009 0.007 0.008
营运资金的变化 -1.661 -0.028 1.877 0.441 -0.608
投资活动产生的现金 -0.002 -0.043 -0.019 -0.004 3.046
资本支出 -0.002 -0.043 -0.019 -0.004 -0.004
其他投资现金流量项目,总计 0 3.05
融资活动产生的现金 0 23.093 48.452 6.56 3.104
融资现金流项目 0 -0.977 -2.034 -0.372 -0.117
股票的发行(报废),净额 0 24.07 50.894 7.281 3.532
债务的发行(退还),净额 0 -0.408 -0.349 -0.311
现金净变化 -10.914 4.288 40.708 1.755 -2.094
Cash Taxes Paid 0 0 0.009 -0.167
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -1.346 -9.926 -8.752 -6.419 -3.272
Cash From Operating Activities -1.595 -10.912 -9.418 -6.92 -4.298
Cash From Operating Activities 0.004 0.02 0.015 0.011 0.005
Non-Cash Items 0.229 0.655 0.511 0.387 0.192
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0 0 0 0 0
Changes in Working Capital -0.482 -1.661 -1.192 -0.899 -1.223
Cash From Investing Activities 0 -0.002 -0.002 -0.002 -0.002
Capital Expenditures 0 -0.002 -0.002 -0.002 -0.002
Cash From Financing Activities 0 0 0 0 0
Financing Cash Flow Items 0 0 0 0 0
Issuance (Retirement) of Stock, Net 0 0 0 0
Net Change in Cash -1.595 -10.914 -9.42 -6.922 -4.3
Issuance (Retirement) of Debt, Net
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
Cable Car Capital LLC Investment Advisor/Hedge Fund 27.7614 4000452 0 2023-02-15 HIGH
BML Capital Management LLC Investment Advisor 4.9058 706930 -151326 2023-03-31 MED
Newtyn Management, LLC Hedge Fund 3.6069 519765 -18513 2023-03-31 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.2422 467205 7800 2023-03-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.8185 262046 1050 2023-03-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.08 155635 0 2023-03-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.4971 71637 0 2023-03-31 LOW
Murchinson Ltd. Investment Advisor/Hedge Fund 0.3664 52800 2207 2023-03-31 LOW
Ozeroff (Christopher David) Individual Investor 0.3537 50970 0 2023-02-15 LOW
Conway (Robert E) Individual Investor 0.347 50000 0 2023-02-15 LOW
Bridgeway Capital Management, LLC Investment Advisor 0.3258 46948 0 2023-03-31 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.2949 42502 0 2023-03-31 LOW
Dekker (C Jeffrey) Individual Investor 0.2776 40000 40000 2022-12-08
Renaissance Technologies LLC Hedge Fund 0.2755 39700 4500 2023-03-31 HIGH
Tekla Capital Management LLC Investment Advisor 0.2253 32461 0 2023-03-31 LOW
Citadel Advisors LLC Hedge Fund 0.175 25211 19730 2023-03-31 HIGH
Group One Trading, L.P. Research Firm 0.1596 23000 23000 2023-03-31 HIGH
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.1456 20982 3465 2023-03-31 LOW
Marquette Wealth Management Investment Advisor 0.1202 17318 0 2023-03-31 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.104 14988 14988 2023-03-31 LOW

为什么选择 Capital.com?让我们的数字来说话。

Capital.com Group

535K+

交易者

87K+

每月活跃客户

$113M+

每月投资额

$64M+

每月提取金额

交易计算器

如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。

交易佣金
0
  • 1:1
杠杆
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投资
交易规模(杠杆 x 投资):
開倉

平仓

做空 做多

ARCA Biopharma Company profile

关于 ARCA Biopharma

ARCA生物制药公司(ARCA)是一家生物制药公司。 公司专注于心血管疾病靶向疗法的开发和商业化。 公司的主导产品包括重组线虫抗凝血蛋白c2,或rNAPc2(AB201)和Gencaro(盐酸布心洛尔)。rNAPc2(AB201)是治疗由核糖核酸(RNA)、病毒引起的疾病,重点是COVID-19,即由SARS-CoV-2病毒引起的疾病综合症。 Gencaro(bucindolol hydrochloride)是一种药物基因靶向的β-肾上腺素能受体拮抗剂,具有温和的血管扩张特性,用于治疗心力衰竭患者的心房颤动(AF)。 房颤是心律失常的一种形式,是心脏正常节律或速率的破坏。 公司正在进行rNAPc2(AB201)的II期b临床试验,ASPEN-COVID-19。 它还在进行Gencaro的IIB/III期临床试验。

Industry: Bio Therapeutic Drugs

Suite 430
8001 Arista Place
BROOMFIELD
COLORADO 80021
US

收入报表

  • Annual
  • Quarterly

人们也观看

Oil - Crude

71.98 Price
+2.450% 1D Chg, %
多头隔夜费 -0.0201%
空头隔夜费 -0.0018%
隔夜费时间 21:00 (UTC)
价差 0.04

US100

14,557.80 Price
+0.640% 1D Chg, %
多头隔夜费 -0.0255%
空头隔夜费 0.0032%
隔夜费时间 21:00 (UTC)
价差 3.0

BTC/USD

27,183.40 Price
+0.300% 1D Chg, %
多头隔夜费 -0.0616%
空头隔夜费 0.0137%
隔夜费时间 21:00 (UTC)
价差 60.00

XRP/USD

0.53 Price
+0.500% 1D Chg, %
多头隔夜费 -0.0753%
空头隔夜费 0.0069%
隔夜费时间 21:00 (UTC)
价差 0.00441

还在找一位您可以信任的经纪商吗?

加入成为全球535,000万多名交易者的一份子,选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易